Long term treatment with (-)deprenyl reduces the optimal dose as well as the effective dose range for increasing antioxidant enzyme activities in old mouse brain

被引:19
|
作者
Carrillo, MC
Kitani, K
Kanai, S
Sato, Y
Ivy, GO
Miyasaka, K
机构
[1] UNIV TOKYO,FAC MED,RADIOISOTOPE RES INST,BUNKYO KU,TOKYO 113,JAPAN
[2] TOKYO METROPOLITAN INST GERONTOL,DEPT CLIN PHYSIOL,ITABASHI KU,TOKYO 173,JAPAN
[3] NATL INST LONGEV SCI,MORIOKA,AICHI 474,JAPAN
[4] UNIV TORONTO,DIV LIFE SCI,SCARBOROUGH,ON M1C 1A4,CANADA
关键词
(-)deprenyl; superoxide dismutase; catalase; long term treatment; substantia nigra; striatum; brain;
D O I
10.1016/0024-3205(96)00420-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
C57BL mice of the male sex received different doses of (-)deprenyl (0.25, 0.5, 1.0 mg/kg per injection 3 times a week, s.c.) for 3 months beginning at the age of 26 months. At the age of 29 months, animals were sacrificed and superoxide dismutase (SOD) and catalase (CAT) activities were examined in several brain regions. The dose of 0.5 mg/kg (3 times a week) was most effective in increasing SOD and CAT activities in S. nigra, striatum and cerebral cortex but not in hippocampus or cerebellum. The dose of 0.25 mg/kg was also effective in increasing enzyme activities, but the effect was much lower than the dose of 0.5 mg/kg. The magnitudes of increase in enzyme activities with the dose of 0.5 mg/kg, however, were generally much lower than respective values we previously found in animals treated with (-)deprenyl for only 3 weeks. The highest dose of 1.0 mg/kg had negligible effect. Enzyme activities in all groups of animals that were examined 2 weeks after the last (-)deprenyl dose were practically the same as respective control values. Together with the results from our previous study with short term (-)deprenyl treatment in old mice, these results replicate our previous findings in old female rats. We showed that longer term treatment with (-)deprenyl reduces the optimal dose for increasing antioxidant enzyme activities by a factor of 5 to 10. The present study further indicates that longer term treatment with (-)deprenyl also reduces the effective dose range of (-)deprenyl as well as the magnitude of increase of enzyme activities. If the effect of (-)deprenyl for increasing these antioxidant enzyme activities in selective brain regions is causally related to its effect of increasing average life expectancies of animals, the selection of a proper dose of the drug may be a critical factor for life span studies in which the drug is administered for more than one year.
引用
收藏
页码:1047 / 1057
页数:11
相关论文
共 5 条
  • [1] A high dose of long term treatment with deprenyl loses its effect on antioxidant enzyme activities as well as on survivals of Fischer-344 rats
    Carrillo, MC
    Kanai, S
    Kitani, K
    Ivy, GO
    LIFE SCIENCES, 2000, 67 (21) : 2539 - 2548
  • [2] Effects of low and high deprenyl dose on antioxidant enzyme activities in the adult rat brain
    Lalkovicova, Maria
    Horvathova, Frantiska
    Sulla, Igor
    Mihalik, Jozef
    Danielisova, Viera
    GENERAL PHYSIOLOGY AND BIOPHYSICS, 2017, 36 (01) : 83 - 90
  • [3] THE EFFECT OF A LONG-TERM (6 MONTHS) TREATMENT WITH (-)DEPRENYL ON ANTIOXIDANT ENZYME-ACTIVITIES IN SELECTIVE BRAIN-REGIONS IN OLD FEMALE FISCHER-344 RATS
    CARRILLO, MC
    KITANI, K
    KANAI, S
    SATO, Y
    MIYASAKA, K
    IVY, GO
    BIOCHEMICAL PHARMACOLOGY, 1994, 47 (08) : 1333 - 1338
  • [4] Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure
    Luis Sargento
    Andre Vicente Simões
    Susana Longo
    Nuno Lousada
    Roberto Palma dos Reis
    Drugs & Aging, 2016, 33 : 675 - 683
  • [5] Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure
    Sargento, Luis
    Simoes, Andre Vicente
    Longo, Susana
    Lousada, Nuno
    dos Reis, Roberto Palma
    DRUGS & AGING, 2016, 33 (09) : 675 - 683